Epidermal growth factor receptor, somatostatin and bcl-2 in human pancreatic tumor xenografts. An immunohistochemical study.
Xenografted human pancreatic tumors (5 ductal adenocarcinomas, 1 leiomyosarcoma, altogether 26 samples) were investigated about their immunohistochemical expression of epidermal growth factor receptor (EGFR), somatostatin (SS) and bcl-2 protein. The expression of the EGFR varied from tumor to tumor. One originally negative carcinoma became immunoreactive during passagings, one tumor has lost its early positive expression, and in 3 cancer lines a phenotypically constant pattern was seen. SS immunoreactivity was practically absent in all tumor samples. Concerning bcl-2 expression, different staining patterns were observed among the carcinomas, but the leiomyosarcoma has retained its strong positivity during xenograftings. In the PZX-5 carcinoma line that was originally negative, the one month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor.
Semmelweis University of Medicine, First Institute of Pathology and Experimental Cancer Research Ulloi út 26., Budapest, H-1085, Hungary. zalatnai@korb1.sote.hu
A
A
Zalatnai
D000818:Animals; D018270:Carcinoma, Ductal, Breast / Q000737:chemistry*; D066246:ErbB Receptors / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D010190:Pancreatic Neoplasms / Q000737:chemistry*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D013004:Somatostatin / Q000032:analysis*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D019253:Proto-Oncogene Proteins c-bcl-2; D013004:Somatostatin; D066246:ErbB Receptors